[Pharmacotherapy of osteoporosis].
Osteoporosis with increased risk of bone fracture is a disabling syndrome that naturally occurs as long as one ages and moves on two legs. Recent progress in bone cell biology has shed light on the mechanisms underlying the anti-osteoporotic properties of drugs that have been in use for a long time, providing a fresh stage for novel pharmacotherapies. In addition, large scale clinical trials developed in the past decade appear not only to rationalize the clinical utilities of these drugs but also to provide new concepts for the development of new therapeutic modalities. Progress in the fields of basic and clinical research field is briefly reviewed herein.
Koida
Masao
M
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Nagaotogecho 45-1, Hirakata, Osaka 573-0101, Japan.
D019386:Alendronate / Q000494:pharmacology / Q000627:therapeutic use; D000728:Androgens / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001665:Binding Sites; D016723:Bone Remodeling; D002986:Clinical Trials as Topic; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000172:deficiency; D004968:Estrogens, Non-Steroidal / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D007529:Isoflavones; D010006:Osteoblasts; D010010:Osteoclasts; D010024:Osteoporosis / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D048789:Phytoestrogens; D028321:Plant Preparations; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology / Q000627:therapeutic use; D014807:Vitamin D / Q000494:pharmacology / Q000627:therapeutic use; D024482:Vitamin K 2 / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000728:Androgens; D004967:Estrogens; D004968:Estrogens, Non-Steroidal; D007529:Isoflavones; D048789:Phytoestrogens; D028321:Plant Preparations; D020845:Selective Estrogen Receptor Modulators; D024482:Vitamin K 2; D014807:Vitamin D; C030814:menatetrenone; D019386:Alendronate